Safety and Tolerability Clinical Trial of Different Doses of the Immunotherapeutic Drug Mobilan (M-VM3) and Placebo in Patients With Prostate Cancer

1. Failure to obtain Informed consent

2. Clinical or radiological signs of metastases

3. Indication to hormone therapy of prostate cancer

4. Clinically significant cardiovascular diseases:

* Myocardial infarction within 6 months prior the screening

* Unstable stenocardia within 3 months prior the screening

* Severe circulation failure (FC III)

* Clinically significant arrhythmias

* Hypotension (systolic blood pressure \< 86 mm Hg) or bradycardia with HR \< 50 beats per min.

* Uncontrolled arterial hypertension (systolic blood pressure \> 170 mm Hg or diastolic blood pressure \> 105 mm Hg.)

5. Clinically significant CNS diseases at the screening

6. Current infection or another severe or systemic disease which increases risk of treatment sequelae

7. Pituitary gland or adrenal disorders in medical history

8. Other malignant tumors within the last 5 years

9. Other concomitant diseases in medical history which according to Investigator may aggravate during the study, including uncontrolled diabetes mellitus, rectal diseases, rectal fissures, hemorrhoid, rectal polyps, rectostenosis, inflammatory urinary diseases: chronic prostatitis, cystitis, urethral catheter, chronic urine retention.

10. Complicated allergic history, systemic allergic reaction, any dietary allergy, intolerability, limitations or specific diets which according to the Investigator may be a contraindication for subject participation in the present study.

11. Administration of drug products which have a marked effect on immune system within 3 previous months prior the screening, long-term intake of disaggregants (warfarin, low molecular heparin except for ThromboASS).

12. Participation in other clinical studies or administration of investigational drug products within 30 days prior the screening, or persisting adverse reactions of any investigational drug product.

13. Any clinically significant patient's health disorders and/or laboratory abnormalities not enlisted in the Protocol which are identified at the screening, and/or any reason which according to the Investigator may prevent the patient's participation in the study.

14. Drug or alcohol abuse at the screening or in the past which according to the Investigator makes the patient ineligible for participation in the study: intake of more than 5 units of alcohol a week (1 unit of alcohol is equivalent to ½ liter of beer, 200 ml of vine or 50 ml of alcohol) or anamnestic data on alcoholism, narcomania, drug abuse and/or history of significant alcohol or drug abuse inducing drug dependence, within one year prior the screening visit.

15. Vaccination made 14 days prior the study

16. Smoking of more than 10 cigarettes a day

17. Unability to understand or follow study instructions

18. Lack of availability during 29 days after administration of the investigational drug product, fails to follow visit schedule

19. Individual intolerability of the investigational drug product components

Study withdrawal criteria:

1. Any patient may refuse from the study participation on his own wish in any moment on any study stage.

2. Principal Investigator may withdraw any patient from the study in the following cases:

* Investigator makes the decision that a patient should be withdrawn in his own best interests

* Patient develops any serious adverse reactions/events in the screening period

* Patient has been enrolled to the study with violations, or does not follow the protocol requirements

* Patient needs additional treatment in the screening period

3. Sponsor has right to terminate the study in any moment.

4. Regulatory authorities have right to terminate the study in any moment.

What this study is about